In spite of a decrease in the frequency of gastric carcinoma as shown in some statistics this malignoma still is an almost daily challenge in surgery. The prognosis of the gastric cancer, in general, depends upon the time of onset of therapy and the tumor grading. At present, chemotherapy and radiation therapy cannot be regarded as alternatives to surgical therapy. An improvement in the preoperative diagnostic procedures including the use of CT has not altered the prognosis of the gastric carcinoma. The procedure of choice in the treatment of gastric cancer should be total gastrectomy. The only exception to this rule is the small antrum carcinoma of the intestinal type, in which subtotal resection seems sufficient. This should comprise a 4/5-resection of the stomach and should be carried out with the same radicality concerning lymphadenectomy in the extragastric region as in total gastrectomy. The problem of intraluminal recurrency is declining provided that sufficient safety distances are maintained. An additive Brachy-radiation type therapy with intraoperative application of 125Jodine-seeds into remaining metastatic lymph-nodes seem to be a new approach to improve the prognosis of the palliatively resected gastric carcinoma. In our experience esophago-jejunoplication for reestablishment of passage following gastrectomy serves best the demand for creating a food reservoir and in preventing intestino-esophageal reflux. It seems to be of prime importance to prepare the patient psychologically for the loss of the stomach and to endow him with dietary plans for the food intake later on.
Download full-text PDF |
Source |
---|
Eur J Clin Invest
January 2025
Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut, USA.
Background: Several studies have investigated the association between Helicobacter pylori colonization and gastrointestinal malignancies. However, inconsistent results have been found, leaving no clear consensus.
Materials And Methods: Umbrella review of meta-analyses of observational studies aiming to understand the association between Helicobacter pylori colonization and gastrointestinal cancers in humans.
Epstein-Barr virus (EBV) contributes to ~1.5% of human cancers, including lymphomas, gastric and nasopharyngeal carcinomas. In most of these, nearly 80 viral lytic genes are silenced by incompletely understood epigenetic mechanisms, precluding use of antiviral agents such as ganciclovir to treat the 200,000 EBV-associated cancers/year.
View Article and Find Full Text PDFTrends Mol Med
January 2025
Institute of Experimental Internal Medicine, Otto von Guericke University Magdeburg, 39120 Magdeburg, Germany. Electronic address:
Ubiquitinylation of proteins regulates manifold processes and is reversed by deubiquitinylating enzymes (DUBs), which are therefore implicated in a plethora of cellular processes. DUBs are frequently upregulated in many diseases, while in a few cases downregulation of DUBs is associated with disease progression. This review focuses on the involvement of DUBs in the development and progression of gastrointestinal diseases with a particular emphasis on hepatic steatosis and hepatocellular, cholangio-, esophageal, gastric, colorectal, and pancreatic ductal carcinomas.
View Article and Find Full Text PDFAdv Sci (Weinh)
January 2025
Department of Surgery, Center for Cancer Medicine, the Fourth Affiliated Hospital of School of Medicine, International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Irreversible electroporation (IRE) is a novel local tumor ablation technique that can potentially stimulate immune responses. However, IRE alone cannot effectively activate the immune system or prevent distant metastases. Therefore, this study utilized the biocompatibility of Chlorella vulgaris (C.
View Article and Find Full Text PDFCancer Res Commun
January 2025
University of Minnesota, Minnesota, MN, United States.
Neuroendocrine neoplasms (NENs) encompass a diverse set of malignancies with limited precision therapy options. Recently, therapies targeting DLL3 have shown clinical efficacy in aggressive NENs, including small cell lung cancers and neuroendocrine prostate cancers. Given the continued development and expansion of DLL3-targeted therapies, we sought to characterize the expression of DLL3 and identify its clinical and molecular correlates across diverse neuroendocrine and non-neuroendocrine cancers.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!